Identification of novel modifier loci of ApcMin affecting mammary tumor development

Cancer Research

Volumn 67, Issue 23, 2007, Pages 11226-11233

  Wang, Hua ^a,b   Teske, Douglas ^a   Tess, Alyssa ^a   Kohlhepp, Rebecca ^a   Choi, Younjeong ^a   Kendziorski, Christina ^a   Moser, Amy Rapaich ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SUSCEPTIBILITY; CHROMOSOME 18; CHROMOSOME 4; CHROMOSOME 6; CHROMOSOME 9; CONTROLLED STUDY; FEMALE; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCUS; KAPLAN MEIER METHOD; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE SPECIFICITY;

ALKYLATING AGENTS; ALLELES; ANIMALS; CHROMOSOME MAPPING; CROSSES, GENETIC; EFFECT MODIFIERS (EPIDEMIOLOGY); ETHYLNITROSOUREA; FEMALE; GENES, APC; GENETIC PREDISPOSITION TO DISEASE; HYPERPLASIA; INTESTINAL NEOPLASMS; MALE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL;

EID: 37049035726     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2487     Document Type: Article

References (43)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Easton DF, Pooley KA, Dunning AM, et al. Genomewide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-93.
3. Balmain A. Cancer as a complex genetic trait: tumor susceptibility in humans and mouse models. Cell 2002;108:145-52.
4. Cardiff RD, Aguilar-Cordova E. Proto-neoplasia revisited: the molecular biology of mouse mammary hyperplasia. Anticancer Res 1988;8:925-33.
5. Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD, Jr., Simpson JF. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 2003;361:125-9.
6. Moser A, Mattes E, Dove W, Lindstrom M, Haag J, Gould M. ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. PNAS 1993;90:8977-81.
7. Min /+ mice. Cancer Res 2001;61:3480-5.
8. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991;66:589-600.
9. Nishisho I, Nakamura Y, Miyoshi Y, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253:665-9.
10. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992;256:668-70.
11. Dietrich WF, Lander ES, Smith JS, et al. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell 1993;75:631-9.
12. MacPhee M, Chepenik KP, Liddell RA, Nelson KK, Siracusa LD, Buchberg AM. The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 1995;81:957-66.
13. Rubinfeld B, Souza B, Albert I, et al. Association of the APC gene product with β-catenin. Science 1993;262:1731-4.
14. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51.
15. Michaelson JS, Leder P. β-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland. Oncogene 2001;20:5093-9.
16. Schoenenberger CA, Andres AC, Groner B, van der Valk M, LeMeur M, Gerlinger P. Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein gene transcription. EMBO J 1988;7:169-75.
17. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994;369:669-71.
18. Gillett C, Smith P, Gregory W, et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer 1996;69:92-9.
19. Furuuchi K, Tada M, Yamada H, et al. Somatic mutations of the APC gene in primary breast cancers. Am J Pathol 2000;156:1997-2005.
20. Zhang SY, Caamano J, Cooper F, Guo X, Klein-Szanto AJ. Immunohistochemistry of cyclin D1 in human breast cancer. Am J Clin Pathol 1994;102:695-8.
21. Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative in situ analysis of β-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 2006;66:5487-94.
22. Lin S-Y, Xia W, Wang JC, et al. β-Catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. PNAS 2000;97:4262-6.
23. Truett GE, Heeger P, Mynatt RL, Truett AA, Walker JA, Warman ML. Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). Biotechniques 2000;29:52-4.
24. Broman KW, Wu H, Sen S, Churchill GA. R/qtl: QTL mapping in experimental crosses. Bioinformatics 2003;19:889-90.
25. Bilger A, Bennett LM, Carabeo RA, et al. A potent modifier of liver cancer risk on distal mouse chromosome 1: linkage analysis and characterization of congenic lines. Genetics 2004;167:859-66.
26. Lan H, Kendziorski CM, Haag JD, Shepel LA, Newton MA, Gould MN. Genetic loci controlling breast cancer susceptibility in the Wistar-Kyoto rat. Genetics 2001;157:331-9.
27. Schwarz G. Estimating the dimension of a model. Ann Stat 1978;6:461-4.
28. Li R, Lyons MA, Wittenburg H, Paigen B, Churchill GA. Combining data from multiple inbred line crosses improves the power and resolution of quantitative trait loci mapping. Genetics 2005;169:1699-709.
29. Going JJ. Stages on the way to breast cancer. J Pathol 2003;199:1-3.
30. Zhu K, Bernard LJ, Levine RS, Williams SM. Estrogen receptor status of breast cancer: a marker of different stages of tumor or different entities of the disease? Med Hypotheses 1997;49:69-75.
31. Czarnomska A, Krysiak E, Piskorowska J, et al. Opposite effects of modifiers of the ApcMin mutation in intestine and mammary gland. Cancer Res 2003;63:4533-7.
32. Fijneman RJ, Jansen RC, van der Valk MA, Demant P. High frequency of interactions between lung cancer susceptibility genes in the mouse: mapping of Sluc5 to Sluc14. Cancer Res 1998;58:4794-8.
33. Nagase H, Mao JH, de Koning JP, Minami T, Balmain A. Epistatic interactions between skin tumor modifier loci in interspecific (spretus/musculus) backcross mice. Cancer Res 2001;61:1305-8.
34. Fijneman RJ, de Vries SS, Jansen RC, Demant P. Complex interactions of new quantitative trait loci, Sluc1, Sluc2, Sluc3, and Sluc4, that influence the susceptibility to lung cancer in the mouse. Nat Genet 1996;14:465-7.
35. Ruivenkamp CA, Csikos T, Klous AM, van Wezel T, Demant P. Five new mouse susceptibility to colon cancer loci, Scc11-15. Oncogene 2003;22:7258-60.
36. Darvasi A. Experimental strategies for the genetic dissection of complex traits in animal models. Nat Genet 1998;18:19-24.
37. Le Voyer T, Lu Z, Babb J, Lifsted T, Williams M, Hunter KW. An epistatic interaction controls the latency of a transgene-induced mammary tumor. Mamm Genome 2000;11:883-9.
38. Le Voyer T, Rouse J, Lu Z, Lifsted T, Williams M, Hunter KW. Three loci modify growth of a transgene-induced mammary tumor: suppression of proliferation associated with decreased microvessel density. Genomics 2001;74:253-61.
39. Gould KA, Tochacek M, Schaffer BS, et al. Genetic determination of susceptibility to estrogen-induced mammary cancer in the ACI rat: mapping of Emca1 and Emca2 to chromosomes 5 and 18. Genetics 2004;168:2113-25.
40. Schaffer BS, Lachel CM, Pennington KL, et al. Genetic bases of estrogen-induced tumorigenesis in the rat: mapping of loci controlling susceptibility to mammary cancer in a Brown Norway x ACI intercross. Cancer Res 2006;66:7793-800.
41. Maitra A, Wistuba II, Washington C, et al. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol 2001;159:119-30.
42. Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelotyping of human lung cancer and peneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000;60:1949-60.
43. An H-X, Claas A, Savelyeva L, et al. Two regions of deletion in 9p23-24 in sporadic breast cancer. Cancer Res 1999;59:3941-3.